NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 01:53PM ET
44.59
Dollar change
+1.16
Percentage change
2.67
%
IndexRUT P/E- EPS (ttm)-3.54 Insider Own37.32% Shs Outstand46.04M Perf Week2.39%
Market Cap2.65B Forward P/E- EPS next Y-5.51 Insider Trans-0.26% Shs Float37.32M Perf Month21.70%
Enterprise Value2.15B PEG- EPS next Q-1.09 Inst Own88.24% Short Float24.59% Perf Quarter19.35%
Income-205.39M P/S- EPS this Y-33.60% Inst Trans28.23% Short Ratio12.47 Perf Half Y-5.49%
Sales0.00M P/B3.94 EPS next Y-25.02% ROA-26.71% Short Interest9.18M Perf YTD-1.57%
Book/sh11.31 P/C5.17 EPS next 5Y-21.59% ROE-27.85% 52W High63.50 -29.78% Perf Year11.61%
Cash/sh8.62 P/FCF- EPS past 3/5Y-105.02% - ROIC-30.15% 52W Low26.20 70.19% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility4.87% 5.87% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-72.82% Oper. Margin- ATR (14)2.27 Perf 10Y-
Dividend Ex-Date- Quick Ratio15.82 Sales Y/Y TTM- Profit Margin- RSI (14)62.61 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio15.82 EPS Q/Q-48.72% SMA206.98% Beta1.48 Target Price93.88
Payout- Debt/Eq0.02 Sales Q/Q- SMA5012.80% Rel Volume0.85 Prev Close43.43
Employees196 LT Debt/Eq0.01 EarningsMay 12 BMO SMA2002.45% Avg Volume735.86K Price44.59
IPOJul 14, 2023 Option/ShortYes / Yes EPS/Sales Surpr.21.84% - Trades Volume431,730 Change2.67%
Date Action Analyst Rating Change Price Target Change
Mar-13-25Initiated Citigroup Buy $95
Nov-25-24Initiated Canaccord Genuity Buy $89
May-10-24Initiated BofA Securities Buy $80
Dec-20-23Initiated BTIG Research Buy $43
Aug-08-23Initiated Wedbush Outperform $40
Aug-08-23Initiated TD Cowen Outperform
Aug-08-23Initiated Stifel Buy $34
Aug-08-23Initiated Jefferies Buy $29
Aug-08-23Initiated Guggenheim Buy $29
Jun-09-25 09:55AM
May-29-25 07:30AM
May-21-25 09:55AM
May-12-25 02:21PM
06:05AM
06:00AM Loading…
06:00AM
06:00AM
May-05-25 09:55AM
May-01-25 08:00AM
Apr-14-25 08:04AM
Mar-26-25 05:50PM
Mar-03-25 12:16PM
06:05AM
06:00AM
Mar-01-25 09:22AM
04:00PM Loading…
Feb-28-25 04:00PM
Feb-25-25 07:30AM
Feb-03-25 07:00AM
Jan-30-25 03:44PM
Jan-29-25 07:30AM
Dec-10-24 07:00AM
Dec-03-24 06:52AM
Dec-02-24 06:00AM
Nov-29-24 01:00PM
Nov-18-24 07:30AM
Nov-13-24 07:21AM
Nov-12-24 07:00AM
Nov-04-24 07:30AM
Oct-24-24 08:00AM
Oct-16-24 07:00AM
04:50PM Loading…
Oct-07-24 04:50PM
Oct-04-24 01:03PM
Sep-12-24 07:00AM
Sep-09-24 07:00AM
Sep-07-24 01:45AM
Aug-24-24 01:30AM
Aug-19-24 07:00AM
Aug-12-24 06:30AM
Aug-10-24 01:00AM
01:00AM
Jul-18-24 08:00AM
Jul-06-24 01:00AM
01:00AM
May-28-24 07:30AM
May-23-24 07:30AM
May-15-24 04:01PM
May-13-24 01:53PM
07:42AM
07:00AM
May-10-24 10:13AM
May-08-24 01:28PM
May-06-24 08:00AM
Apr-03-24 07:49AM
Mar-28-24 11:01AM
Mar-25-24 07:00AM
07:00AM
Mar-12-24 04:01PM
Mar-07-24 06:49PM
Mar-05-24 10:53PM
04:23PM
04:16PM
07:35AM
07:35AM
06:10AM
06:00AM
06:00AM
Mar-04-24 04:01PM
Jan-02-24 07:30AM
Nov-15-23 04:44AM
Nov-13-23 07:30AM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
Sep-27-23 08:42AM
Sep-14-23 07:30AM
Aug-29-23 08:00AM
Aug-28-23 07:30AM
Aug-21-23 07:30AM
Aug-10-23 02:29PM
Aug-08-23 10:02AM
Aug-07-23 07:30AM
Aug-04-23 06:30PM
Aug-02-23 07:30AM
Jul-18-23 04:01PM
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dambkowski CarlChief Medical OfficerJun 04 '25Sale36.962,725100,716241,723Jun 06 08:01 PM
Dambkowski CarlChief Medical OfficerMay 07 '25Sale35.752,72597,419244,448May 09 08:01 PM
Dambkowski CarlChief Medical OfficerApr 02 '25Sale36.223,860139,801247,173Apr 04 08:01 PM
CARL DAMBKOWSKIOfficerApr 02 '25Proposed Sale35.619,310331,529Apr 02 04:23 PM
Dambkowski CarlChief Medical OfficerMar 05 '25Sale30.481,59048,463251,033Mar 07 08:02 PM
HENDERSON MICHAEL THOMASChief Executive OfficerMar 05 '25Sale30.1510,000301,5111,292,987Mar 07 08:01 PM
HENDERSON MICHAEL THOMASOfficerMar 05 '25Proposed Sale30.1510,000301,501Mar 05 01:46 PM
Dambkowski CarlChief Medical OfficerFeb 05 '25Option Exercise22.8679518,174256,143Feb 07 08:02 PM
Dambkowski CarlChief Medical OfficerFeb 05 '25Sale40.693,520143,229252,623Feb 07 08:02 PM
HENDERSON MICHAEL THOMASChief Executive OfficerFeb 05 '25Sale40.5815,000608,7001,302,987Feb 07 08:01 PM
HENDERSON MICHAEL THOMASDirectorFeb 05 '25Proposed Sale40.5815,000608,728Feb 05 02:02 PM
HENDERSON MICHAEL THOMASChief Executive OfficerJan 31 '25Option Exercise22.868,500194,3101,317,987Jan 31 08:00 PM
HENDERSON MICHAEL THOMASChief Executive OfficerJan 08 '25Sale48.8515,000732,6931,309,487Jan 10 08:00 PM
HENDERSON MICHAEL THOMASOfficerJan 08 '25Proposed Sale48.8415,000732,675Jan 08 12:23 PM
Dambkowski CarlChief Medical OfficerJan 02 '25Option Exercise22.861,36031,090259,433Jan 03 08:00 PM
Dambkowski CarlChief Medical OfficerJan 02 '25Sale46.944,085191,740255,348Jan 03 08:00 PM
McKenna Mark C.DirectorDec 12 '24Buy49.5420,000990,77520,000Dec 16 06:00 AM
Dambkowski CarlChief Medical OfficerDec 11 '24Option Exercise22.861,81541,491262,613Dec 13 08:01 PM
Dambkowski CarlChief Medical OfficerDec 11 '24Sale48.764,540221,363258,073Dec 13 08:01 PM
CARL DAMBKOWSKIOfficerDec 11 '24Proposed Sale48.3818,160878,581Dec 11 04:59 PM
Dambkowski CarlChief Medical OfficerDec 04 '24Sale46.076,665307,057260,798Dec 06 08:02 PM
HENDERSON MICHAEL THOMASChief Executive OfficerDec 04 '24Sale46.5815,000698,6541,324,487Dec 06 08:01 PM
HENDERSON MICHAEL THOMASOfficerDec 04 '24Proposed Sale46.5815,000698,709Dec 04 11:12 AM
Dambkowski CarlChief Medical OfficerNov 06 '24Sale59.126,665394,041267,463Nov 08 08:02 PM
HENDERSON MICHAEL THOMASChief Executive OfficerNov 06 '24Sale59.2215,000888,3201,339,487Nov 08 08:01 PM
HENDERSON MICHAEL THOMASOfficerNov 06 '24Proposed Sale59.2315,000888,388Nov 06 11:39 AM
Dambkowski CarlChief Medical OfficerOct 02 '24Sale56.266,665374,954274,128Oct 04 08:02 PM
HENDERSON MICHAEL THOMASChief Executive OfficerOct 02 '24Sale56.2340,0002,249,3071,354,487Oct 04 08:01 PM
CARL DAMBKOWSKIOfficerOct 02 '24Proposed Sale57.3116,010917,533Oct 02 04:20 PM
HENDERSON MICHAEL THOMASOfficerOct 02 '24Proposed Sale56.2340,0002,249,176Oct 02 02:34 PM
Dambkowski CarlChief Medical OfficerSep 04 '24Sale47.566,665316,969280,793Sep 06 08:03 PM
HENDERSON MICHAEL THOMASChief Executive OfficerSep 04 '24Sale47.6240,0001,904,8411,394,487Sep 06 08:02 PM
HENDERSON MICHAEL THOMASOfficerSep 04 '24Proposed Sale47.6240,0001,904,848Sep 04 01:35 PM
Henderson JaneChief Financial OfficerAug 23 '24Sale48.266,000289,560200,871Aug 23 08:05 PM
JANE V HENDERSONOfficerAug 23 '24Proposed Sale48.266,000289,570Aug 23 04:09 PM
Dambkowski CarlChief Medical OfficerAug 07 '24Sale40.677,335298,336287,458Aug 09 08:05 PM
HENDERSON MICHAEL THOMASChief Executive OfficerAug 07 '24Sale40.6240,0001,624,7641,434,487Aug 09 08:05 PM
HENDERSON MICHAEL THOMASOfficerAug 07 '24Proposed Sale40.6240,0001,624,784Aug 07 01:18 PM
HENDERSON MICHAEL THOMASChief Executive OfficerJul 05 '24Sale37.2615,000558,9001,474,487Jul 05 08:01 PM
Dambkowski CarlChief Medical OfficerJul 03 '24Sale37.605,995225,418294,793Jul 05 08:01 PM